Company
RespireRx Pharmaceuticals
OTCMKTS:RSPI
RespireRx Pharmaceuticals Inc is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling. It is developing treatment options that address conditions that affect millions of people, but for which there are limited or poor treatment options, including obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, spinal cord injury (SCI).
24 stories · page 2 of 2
RespireRx Pharmaceuticals CEO announces internal restructuring, plans further clinical trials in 2022
The company has implemented an internal restructuring plan through which its two-drug platforms have been reorganized into separate business units and may in the future be organized into private subsidiaries of RespireRx
RespireRx Pharmaceuticals notes publication of paper on GABAkine KRM-II-81, which it is advancing for epilepsy and pain
RespireRx is advancing a portfolio of innovative drugs to combat neurological and psychiatric conditions and its EndeavourRx business unit is advancing KRM-II-81 to treat epilespy and chronic pain
RespireRx Pharmaceuticals is advancing an innovative portfolio targeting poorly or unmet patient need
With a market cap of US$1.7 million, the company aims to develop treatments, based on modifying neurotransmission (brain signalling), which have advantages to currently available drugs, if there are any